Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News ProMIS Neurosciences T.PMN

Alternate Symbol(s):  ARFXD

ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinson's disease, and dementia with Lewy bodies. It primarily operates in Canada.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (TSX:PMN)

Fundamentals Snapshot (TSX:PMN)

Bullboard Posts (TSX:PMN)

RE:New ceo

Fantastic RC, so what progressive initiative do you see her bringing before the first P1 results? 
M101 - 10 hours ago

New ceo

Had a chance recently to meet the new ceo.  Pretty darn impressed with this lady considering she has only been on the job for 4 days...
retiredcop - 14 hours ago

RE:RE:RE:RE:RE:RE:biogen suffering ?

The difference with PMN310 has always been there. Targetting toxic oligomers. It can't be clearer than that. ProMIS has always made...
G1945V - 19 hours ago

RE:313% upside?

Darn, everytime these guys say this the price goes down and they have repeated this. Keeping  friendly ties for PP's.
FarmerBetty - 1 day ago

313% upside?

https://www.cantechletter.com/2022/09/promis-neurosciences-has-a-313-per-cent-upside-says-leede-jones-gable/# "Leede Jones Gable...
BottomBroker - 1 day ago

RE:RE:RE:RE:RE:biogen suffering ?

I hope she leverages the modest benefit of lecanemab into a promotional strategy that stresses PMN310s differences rather than...
M101 - 1 day ago